CBS 2019
CBSMD教育中心
English

推荐文献

科研文章

荐读文献

Major trials in coronary intervention from 2018 Relation of prior statin and anti-hypertensive use to severity of disease among patients hospitalized with COVID-19: Findings from the American Heart Association’s COVID-19 Cardiovascular Disease Registry Multimodality imaging in cardiology: a statement on behalf of the Task Force on Multimodality Imaging of the European Association of Cardiovascular Imaging A Novel Algorithm for Treating Chronic Total Coronary Artery Occlusion ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization: A Report by the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology Endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography Management of two major complications in the cardiac catheterisation laboratory: the no-reflow phenomenon and coronary perforations Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management Microthrombi As A Major Cause of Cardiac Injury in COVID-19: A Pathologic Study Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial

Original Research2022 Jun 20;e13826.

JOURNAL:Eur J Clin Invest. Article Link

Prognostic implication of lipidomics in patients with coronary total occlusion undergoing PCI

Y Zhou, XD Wang, JY Qian et al. Keywords: biomarker; CTO; CAD; lipidomics; risk prediction

ABSTRACT

BACKGROUND - Predictors of prognosis in patients with coronary chronic total occlusion (CTO) undergoing elective percutaneous coronary intervention (PCI) have remained lacking. Lipidomic profiling enable researchers to associated lipid species with disease progression and may improve the prediction of cardiovascular events.


METHODS In the present study, 781 lipids were measured by targeted lipidomic profiling in 350 individuals (50 healthy controls, 50 patients with coronary artery disease and 250 patients with CTO). L1-regularized logistic regression was used to identify lipid species associated with adverse cardiovascular events and create predicting models which were verified by 10-fold cross-validation (200 repeats). Comparisons were made between a traditional model constructed with clinical characteristics alone and a combined model built with both lipidomic data and traditional factors.


RESULTS 24 lipid species were dysregulated exclusively in patients with CTO, most of which belonged to sphingomyelin (SM) and triacylglycerol (TAG). Compared with traditional risk factors, new model combining lipids and traditional factors had significantly improved performance in predicting adverse cardiovascular events in CTO patients after PCI (area under the curve, 0.870 vs. 0.726, p < 0.05; Akaike information criterion, 129 vs. 156; net reclassification improvement, 0.312, p < 0.001; integrated discrimination improvement, 0.244, p < 0.001). Nomogram was built based on the incorporated model and prove efficient by Kaplan-Meier method.


CONCLUSIONS - Lipidomic profiling revealed lipid species which may participated in the formation of CTO and could contribute to the risk stratification in CTO patients undergoing PCI.